Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Профилактика и лечение патологии костной ткани при злокачественных новообразованиях

Список литературы

  1. В порядке цитированияв тексте;
  2. Ссылки в тексте приводятся в квадратных скобках;
  3. Единый стиль (ГОСТы.);
  4. Указание страниц обязательно
  5. Hadji P.Aapro M.S.Body J.J.et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.J Bone Oncol. 2017; 7: 1-12
  6. Ingangi V.,Minopoli M.,Ragone C.et al. Role of microenvironment on the fate of disseminating cancer stem cells. Front Oncol. 2019; 9: 82
  7. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12: 6243s-6249s
  8. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520-2526
  9. International osteoporosis foundation 2011. Johnell, O. and J.A. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 2006. 17(12): p. 1726-33.
  10. Остеопороз в онкологической практике: современные подходы к лекарственной коррекции С.Г. Багрова, Онкогинекология №1, 2015, стр 55-62
  11. Использование остеомодифицирующих агентов (ома) для профилактики и лечения патологии костной ткани при злокачественных новообразованиях: Багрова С.Г., Копп М.В., Кутукова С.И., Манзюк Л.В., Семиглазова Т.Ю. DOI: 10.18027/2224-5057-2020-10-3s2-38 von Moos R. Costa L.Gonzalez-Suarez E.et al.
  12. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody.Cancer Treat Rev. 2019; 76: 57-67
  13. Eastell R.,O'Neill T.W.,Hofbauer L.C. et al.Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016; 2: 16069
  14. Broski S.M.,Young J.R.,Kendi A.T., Subramaniam R.M.
  15. Skeletal metastasis evaluation: value and impact of PET/computed tomography on diagnosis, management and prognosis. PET Clin. 2019; 14: 103-120
  16. Г.А. Мельниченко, Ж.Е. Белая, Л.Я. Рожинская и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии 2017;63(6):392-426 ,
  17. Shapiro C.L.,Van Poznak C.,Lacchetti C.,et al.Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline.J Clin Oncol. 2019; 37: 2916-2946
  18. Bonakdarpour A., Reinus W.R., Khurana J.S. Editors. Diagnostic Imaging of Musculoskeletal Diseases. A Systematic Approach // Springer Science+Business Media, LLC. - 2010. - P.302-308
  19. Galasko CS: The value of scintigraphy in malignant disease. Cancer Treat Rev 2:225-272, 1975
  20. Лишманов Ю.Б., Чернов В.И. Радионуклидная диагностика для практических врачей. - Томск, 2004. - С.280- 285
  21. Shie P., Cardarelli R., Brandon D., Erdman W., Abdulrahim N. Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008;33:97-101. DOI: 10.1097/RLU.0b013e31815f23b7
  22. Chang MC, Chen JH, Liang JA, Lin CC, Yang KT, Cheng KY, Yeh JJ, Kao CH. Metaanalysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol. 2012 Mar;19(3):349-57. doi: 10.1016/j.acra.2011.10.018.
  23. Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y.Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis..Skeletal Radiol.
  24. 2019 Dec;48(12):1915-1924. doi: 10.1007/s00256-019-03230-z
  25. Galasko CS, Doyle FH: The detection of skeletal metastases from mammary cancer: A regional comparison between radiology and scintigraphy. Clin Radiol 23:295-297, 1972 Vogel CL, Schoenfelder J, Shemano I et al. Worsening bone scan in the evaluation
  26. of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13: 1123-1128. DOI: 10.1200/JCO.1995.13.5.1123
  27. Coleman RE, Mashiter G, Whitaker KB et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988; 29: 1354-1359
  28. Woolf D.K., Padhani A.R., Makris A. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Annals of Oncology 26: 10481057, 2015 DOI:https://doi.org/10.1093/annonc/mdu558
  29. Citrin D.L., Bessent R.G., Greig W.R. A comparison of the sensitivity and ac-curacy of the 99m Tc-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases // Clin Radiol. — 1977. — Vol. 28. —P. 107-117
  30. Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a metaanalysis comparing 18FDG PET, CT, MRI and bone scintigraphy. European Radiology 2011; 21(12): 2604-2617. DOI: 10.1007/s00330-011-2221-4
  31. Eisenhauera E.A., Therasseb P., Bogaertsc J., Schwartzd L.H., Sargente D. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026
  32. Hamaoka T, Costelloe CM, Madewell 8JE et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 2010; 102: 651-657
  33. Umbehr M.H., Muntener M., Hany T., Sulser T., Bachmann L.M. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013 Jul;64(1):106-17. doi: 10.1016/j.eururo.2013.04.019
  34. Harmon S.A, Bergvall E., Mena E., Shih J.H., Adler S., et al. A Prospective Comparison of 18 F-Sodium Fluoride PET/CT and PSMA-Targeted 18 F-DCFBC PET/CT in
  35. Metastatic Prostate Cancer. J Nucl Med. 2018 Nov;59(11):1665-1671. doi: 10.2967/jnumed.117.207373.
  36. Deppen S.A., Blume J., Bobbey A.J., Shah C., Graham M.M., et al. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta
  37. Analysis. J Nucl Med. 2016 Jun;57(6):872-8. doi: 10.2967/jnumed.115.165803
  38. Wahl R.L., Jacene H., Kasamon Y. et al. From RECIST to PERCIST: Evolving
  39. Considerations for PET response criteria in solid tumors // J. Nucl. Med. 2009. Vol. 50. Suppl 1. P. 122S-50S
  40. Veltri, A.; Bargellini, I.; Giorgi, L.; Almeida, P.A.M.S.; Akhan, O. CIRSE Guidelines on Percutaneous Needle Biopsy (PNB). Cardiovasc. Interv. Radiol. 2017, 40, 1501-1513. DOI: 10.1007/s00270-017-1658-5
  41. Criscitiello, C., Andre, F., Thompson, A.M., De Laurentiis, M., Esposito, A., et al.. Biopsy confirmation of metastatic sites in breast cancer patients: Clinical impact and future perspectives. Breast Cancer Res. 2014, 16, 205 doi: 10.1186/bcr3630
  42. Coleman R, et al. Bone health in cancer: ESMO Clinical Practice Guidelines Ann Oncol 2020:S0923-7534(20)39995-6.
  43. D'Oronzo S.,Coleman R.,Brown J.,Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol. 2019; 15: 004 Rosen L.S.,Gordon D.,Kaminski M.et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98: 1735-1744
  44. Otto S., Pautke C.,Van den Wyngaert T.et al. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69: 177-187 de Groot A.F.,Appelman-Dijkstra N.M.,van der Burg S.H.,Kroep J.R.The anti-tumor effect of RANKL inhibition in malignant solid tumors - a systematic review.Cancer Treat Rev. 2018; 62: 18-28
  45. Cummings S.R.,Ferrari S.,Eastell R.,et al.Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018; 33: 190-198
  46. Stopeck A.T.,Lipton A.,Body J.J.,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.J Clin Oncol. 2010; 28: 5132-5139
  47. В.М.Моисеенко. Паллиативное лечение больных солидными опухолями с метастатическим поражением костей. Практическая онкология №1 (5), стр 36-37; 2001
  48. A. Mesfin, D.M.H. El, A. Jain, H. Hassanzadeh, K.M. Kebaish, Total en bloc spon-dylectomy for primary and metastatic spine tumors, Orthopedics 38 (11) (2015) 995-1000 Huang, H. Wei, W. Cai, et al., Total en bloc spondylectomy for solitary metastatictumors of the fourth lumbar spine in a posterior-only approach, World Neurosurg (2018).
  49. Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004;22:300-306.
  50. Валиев, А.К. Хирургическое лечение метастатического поражения костей / А.К. Валиев, Э.Р. Мусаев, Е.А. Сушенцов, М.Д. Алиев // Практическая онкология. - 2011. - Т. 12, № 3. - С. 112-116
  51. Rose, P.S. Minimally invasive treatment of spinal metastases: techniques / P.S. Rose, M.B. Dekutoski, M.J. Clarke // Int. J. Surg. Oncol. - 2011. - Vol. 2011. - P. 1-6.
  52. Patchell, R.A. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial / R.A. Patchell, P.A. Tibbs, W.F. Regine et al. // Lancet. - 2005. - Vol. 366, N 9486. - P. 643-648.
  53. Lutz S, Balboni T, Jones J, Lo S, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology (2017) 7, 4-12;
  54. Huisman M, van den Bosch MA, Wijlemans JW, et al. Effectiveness of reirradiation for painful bone metastases: A systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 012;84:8-14.
  55. Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112-124.
  56. Baczyk M, Milecki P, Pisarek M, et al. A prospective randomized trial: A comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases. Neoplasma. 2013;60:328-333.
  57. 50 Стенина М.Б., Жукова Л.Г., Королева И.А., Пароконная А.А., Семиглазова Т.Ю., Тюляндин С.А., Фролова М.А. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. - 2018. -том 8, С. 113-144

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*